These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12546271)

  • 1. A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
    Nambi V; Hoogwerf BJ; Sprecher DL
    Cleve Clin J Med; 2002 Dec; 69(12):985-9. PubMed ID: 12546271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.
    Grundy SM
    Am J Cardiol; 1999 May; 83(9B):25F-29F. PubMed ID: 10357572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-sensitising agents in polycystic-ovary syndrome.
    Sattar N; Hopkinson ZE; Greer IA
    Lancet; 1998 Jan; 351(9099):305-7. PubMed ID: 9652605
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.
    Gouni-Berthold I; Berthold HK
    Curr Pharm Des; 2014; 20(31):5025-38. PubMed ID: 24320031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Satoh J
    Nihon Rinsho; 2003 Jul; 61(7):1224-9. PubMed ID: 12877089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    Ayyobi AF; Brunzell JD
    Am J Cardiol; 2003 Aug; 92(4A):27J-33J. PubMed ID: 12957324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome.
    Venkatapuram S; Shannon RP
    Am J Ther; 2006; 13(1):64-71. PubMed ID: 16428924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes in metabolic syndrome.
    Bhatheja R; Bhatt DL
    J Cardiovasc Nurs; 2006; 21(4):298-305. PubMed ID: 16823284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome.
    Bestermann W; Houston MC; Basile J; Egan B; Ferrario CM; Lackland D; Hawkins RG; Reed J; Rogers P; Wise D; Moore MA
    Am J Med Sci; 2005 Jun; 329(6):292-305. PubMed ID: 15958871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of syndrome X in daily practice].
    Daubresse JC
    Rev Med Brux; 2000 Dec; 21(6):473-7. PubMed ID: 11194491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hypertension associated with diabetes mellitus].
    Katayama S
    Nihon Rinsho; 1997 Aug; 55(8):2091-6. PubMed ID: 9284429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome.
    Giles TD; Sander GE
    J Clin Hypertens (Greenwich); 2005 Nov; 7(11):669-78. PubMed ID: 16278525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?
    Ehrmann DA
    J Endocrinol Invest; 1998 Oct; 21(9):632-5. PubMed ID: 9856419
    [No Abstract]   [Full Text] [Related]  

  • 17. [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
    Demant T
    Fortschr Med Orig; 2001; 119(1):37-40. PubMed ID: 11935656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome.
    Gogia A; Agarwal PK
    Indian J Med Sci; 2006 Feb; 60(2):72-81. PubMed ID: 16505579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC; Schneider EF; Fonseca VA
    Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.